Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12438437 | 0.95 | HSD17B10 (0.35) | HSD17B10MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL10251711 | 0.91 | HSD17B10 (0.44) | HSD17B10S1PR1 | |
| SCHEMBL10000701 | 0.91 | HSD17B10 (0.44) | HSD17B10S1PR1 | |
| SCHEMBL12747962 | 0.91 | HSD17B10 (0.44) | HSD17B10S1PR1 | |
| SCHEMBL10000706 | 0.91 | HSD17B10 (0.44) | HSD17B10S1PR1 | |
| SCHEMBL19342996 | 0.87 | HSD17B10 (0.38) | HSD17B10KDM4ES1PR1 | |
| SCHEMBL12747959 | 0.86 | HSD17B10 (0.40) | HSD17B10ALDH1A1GAAS1PR1 | |
| SCHEMBL12747968 | 0.86 | HSD17B10 (0.40) | HSD17B10S1PR1 | |
| SCHEMBL18269522 | 0.85 | RAB9A (0.38) | KDM4EALDH1A1 | |
| SCHEMBL444390 | 0.83 | ALDH1A1 (0.39) | HSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9217009-B2 | Version of FDG detectable by single-photon emission computed tomography | MALLINCKRODT LLC (US) | 2015-12-22 | — | — | US | disclosed |
| US-20140378677-A1 | VERSION OF FDG DETECTABLE BY SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY | MALLINCKRODT VETERINARY, INC. | 2014-12-25 | — | — | US | disclosed |
| US-8858916-B2 | Metal chelate linked to a hexose carrier for use as a metallopharmaceutical diagnostic or therapeutic agent | MALLINCKRODT LLC (US) | 2014-10-14 | — | — | US | disclosed |
| US-20140178302-A1 | INTEGRIN TARGETED SYNTHETIC LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | BRACCO IMAGING S.P.A. (IT) | 2014-06-26 | — | — | US | disclosed |
| US-20110177004-A1 | Version of FDG Detectable by Single-Photon Emission Computed Tomography | OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110177004-A1 | Version of FDG Detectable by Single-Photon Emission Computed Tomography | SLC2A1, SLC2A4, SLC2A3 | HSD17B10 1865/4885MEN1 398/4885KMT2A 2498/4885 |
| US-20140178302-A1 | INTEGRIN TARGETED SYNTHETIC LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | ITGA2B, ITGB2, ITGB1 | HSD17B10 4649/4885MEN1 3824/4885KMT2A 3272/4885 |
| US-20140378677-A1 | VERSION OF FDG DETECTABLE BY SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY | SLC2A1, SLC2A4, SLC2A3 | HSD17B10 1865/4885MEN1 398/4885KMT2A 2498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.